Skip to content

A study to assess the safety and efficacy of chemotherapy and surgery in treatment of cervical cancer

Retrospective analysis of neoadjuvant chemotherapy on postoperative treatment in patients with cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN24104022
Enrollment
207
Registered
2022-07-13
Start date
2019-01-01
Completion date
Unknown
Last updated
2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feasibility of NACT in localized advanced cervical cancer patients Cancer

Interventions

The NACT group: FIGO(2009) IB2-IIA2 cervical cancer patients underwent carboplatin-liposomal paclitaxel chemotherapy followed by radical hysterectomy and pelvic lymphadenectomy. The P

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Primary malignant tumor of cervix confirmed by cervical biopsy 2. No other malignant tumors

Exclusion criteria

Exclusion criteria: 1. Cervical metastatic malignant tumor 2. Complicated with other malignant tumors 3. Patients undergoing surgery or pathological examination in other hospitals

Design outcomes

Primary

MeasureTime frame
5-year overall survival defined as the time from completion of operation to death or to the date of last contact.

Secondary

MeasureTime frame
1. 5-year progression-free survival defined as the time from completion of operation to the first appearance of progressive disease or to the date of last contact 2. Cumulative postoperative radiation rate: use of radiation and the interval between surgery and radiation (adjuvant therapy or therapy after recurrence) were used to estimate the cumulative radiation during the follow-up

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 11, 2026